340B PATIENTS Act of 2024

The 340B PATIENTS Act of 2024, also known as Bill 118 s 5021, is a piece of legislation currently being considered by the US Congress. This bill aims to address issues related to the 340B Drug Pricing Program, which allows certain healthcare providers to purchase prescription drugs at discounted prices.

The main goal of the 340B PATIENTS Act is to increase transparency and accountability within the program. The bill includes provisions that require participating healthcare providers to report on how they are using the savings they receive from discounted drug prices. This information will be made publicly available in order to ensure that the program is being used in a way that benefits patients and the healthcare system as a whole.

Additionally, the bill seeks to address concerns about the potential for abuse and misuse of the 340B program. It includes measures to strengthen oversight and enforcement mechanisms, as well as provisions to prevent drug manufacturers from discriminating against certain healthcare providers who participate in the program. Overall, the 340B PATIENTS Act of 2024 aims to improve the effectiveness and integrity of the 340B Drug Pricing Program, ultimately benefiting patients and ensuring that the program is being used in a responsible and ethical manner.